InVivo Therapeutics Announces Appointment of Richard Christopher as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) InVivo Therapeutics Holdings Corp.
Posted on: 14 Jan 19
InVivo Therapeutics Holdings Corp. (Nasdaq:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries (SCIs), today announces the appointment of Richard Christopher as its Chief Financial Officer and Treasurer, effective January 14, 2019.
Prior to joining InVivo, Mr. Christopher was the Chief Financial Officer of iCAD, Inc., a Nasdaq-listed company with a focus on therapies and solutions for the early identification and treatment of cancer. Prior to iCAD, Inc., Mr. Christopher was Chief Financial Officer and Chief Operating Officer of Caliber Imaging & Diagnostics, Inc., a medical technology company focused on cancer detection imaging solutions, with primary applications in dermatology. Prior to Caliber, Mr. Christopher held various positions of increasing responsibility at DUSA Pharmaceuticals, Inc., a Nasdaq-listed dermatology company focused on the treatment of precancerous skin lesions, where he ultimately served as Chief Financial Officer through its acquisition and integration into Sun Pharmaceuticals Industries Ltd. Mr. Christopher holds a Master of Science in Accounting from Suffolk University and a Bachelor of Science in Finance from Bentley University.
Richard Toselli, M.D., InVivo’s President and Chief Executive Officer said, “Rich’s more than 25 years of invaluable financial experience, including at various publicly traded life science companies, make him a key asset in the navigation of InVivo’s goals. He has a proven track record in diverse financial management, financing transactions and strategic planning, and most significantly, Rich shares a passion for bringing treatments and therapies to patients in areas of unmet need. On behalf of the Board and Management, we welcome Rich to the InVivo team.”
“It is an exciting time to join InVivo, especially during